Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

Delcath Announces Third Quarter Fiscal 2018 Financial Results

GlobeNewswire November 13, 2018

Delcath Announces Enrollment of First Patient in ALIGN Trial

GlobeNewswire October 18, 2018

CORRECTING and REPLACING – Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma

GlobeNewswire October 15, 2018

Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma

GlobeNewswire October 15, 2018

Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology

GlobeNewswire October 4, 2018

Delcath Raises $8.1 Million from Shareholders in Rights Offering

GlobeNewswire September 27, 2018

Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018

GlobeNewswire September 26, 2018

Data on Delcath’s PHP Therapy presented at CIRSE 2018

GlobeNewswire September 24, 2018

Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018

GlobeNewswire September 13, 2018

Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology

GlobeNewswire September 4, 2018

Delcath Announces Extension of Rights Offering Period to September 26, 2018

GlobeNewswire August 28, 2018

Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018

GlobeNewswire August 27, 2018

Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification

GlobeNewswire August 23, 2018

Delcath Announces Pending Expiration to Rights Offering Subscription Period

GlobeNewswire August 22, 2018

First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma

GlobeNewswire August 21, 2018

Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial

GlobeNewswire August 20, 2018

Delcath Issues Letter to Stockholders

GlobeNewswire August 17, 2018

Delcath Announces Second Quarter Fiscal 2018 Financial Results

GlobeNewswire August 15, 2018

Delcath Announces Commencement of Rights Offering Subscription Period

GlobeNewswire August 6, 2018

Summary of Calendar for Upcoming Proposed Delcath Rights Offering

GlobeNewswire July 31, 2018